Drugs / ET019003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04014894 | Jun 2019 → Jul 2021 | leukemia, lymphoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET019003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04014894 ↗ |
| Modality | Cell therapy | “generated novel CD19-specific γ/δ TCR-T cells, ET019003” PMID 36681817 ↗ Jan 2023 |
| Route | Other | “after ET019003 infusion” PMID 36681817 ↗ Jan 2023 |
| Target | CD19 | “generated novel CD19-specific γ/δ TCR-T cells” PMID 36681817 ↗ Jan 2023 |